Corebridge Financial Inc. Has $973,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Corebridge Financial Inc. decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,913 shares of the specialty pharmaceutical company’s stock after selling 2,103 shares during the quarter. Corebridge Financial Inc.’s holdings in Supernus Pharmaceuticals were worth $973,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock worth $222,411,000 after purchasing an additional 22,852 shares in the last quarter. Bridge City Capital LLC raised its holdings in shares of Supernus Pharmaceuticals by 0.8% in the 4th quarter. Bridge City Capital LLC now owns 94,997 shares of the specialty pharmaceutical company’s stock worth $3,435,000 after buying an additional 761 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Supernus Pharmaceuticals by 18.9% in the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company’s stock worth $461,000 after buying an additional 2,029 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $1,298,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $1,508,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Cantor Fitzgerald restated a “neutral” rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Insider Buying and Selling

In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction on Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 700 shares of the company’s stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $39.62, for a total value of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares in the company, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock worth $440,263 in the last 90 days. Corporate insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock opened at $32.74 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $25.53 and a 52 week high of $40.28. The stock has a market capitalization of $1.83 billion, a PE ratio of 30.60 and a beta of 0.84. The stock’s fifty day moving average is $34.57 and its 200-day moving average is $35.04.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.